Key statistics
On Tuesday, Ascentage Pharma Group International (6855:HKG) closed at 42.46, 35.44% above the 52 week low of 31.35 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 45.18 |
|---|---|
| High | 45.30 |
| Low | 42.14 |
| Bid | 42.40 |
| Offer | 42.46 |
| Previous close | 45.02 |
| Average volume | 1.37m |
|---|---|
| Shares outstanding | 373.32m |
| Free float | 272.60m |
| P/E (TTM) | -- |
| Market cap | 16.81bn HKD |
| EPS (TTM) | -4.05 HKD |
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences
- Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
- Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
- Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
- Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
- Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
- Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
- Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
- Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
- Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
More ▼
